The presence of the adenovirus E3 region improves the oncolytic potency of conditionally replicative adenoviruses

Clinical Cancer Research

Volumn 8, Issue 11, 2002, Pages 3348-3359

  Suzuki, Kaori ^a   Alemany, Ramón ^a   Yamamoto, Masato ^a   Curie, David T ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; ONCOLYTIC VIRUS; VIRUS PROTEIN; ARGINYL-GLYCYL-ASPARTIC ACID; CRYSTAL VIOLET; OLIGOPEPTIDE;

ADENOVIRUS; ARTICLE; CANCER INHIBITION; COMPARATIVE STUDY; CONTROLLED STUDY; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR XENOGRAFT; VIRUS INFECTIVITY; VIRUS REPLICATION; ANIMAL; BIOLOGICAL MODEL; CANCER TRANSPLANTATION; CELL CULTURE; FEMALE; GENETICS; METABOLISM; MOUSE; NEOPLASM; NUDE MOUSE; PLASMID; SPECTROPHOTOMETRY; TIME;

ADENOVIRIDAE; ADENOVIRUS E3 PROTEINS; ANIMALS; FEMALE; GENTIAN VIOLET; HUMANS; MICE; MICE, NUDE; MODELS, GENETIC; NEOPLASM TRANSPLANTATION; NEOPLASMS; OLIGOPEPTIDES; PLASMIDS; SPECTROPHOTOMETRY; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0036846643     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (67)

1. Bischoff, J. R., Kirn, D. H., Williams, A., Heise, C., Horn, S., Muna, M., Ng, L., Nye, J. A., Sampson-Johannes, A., Fattaey, A., and McCormick, F. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science (Wash. DC), 274: 373-376, 1996.
2. Rodriguez, R., Schuur, E. R., Lim, H. Y., Henderson, G. A., Simons, J. W., and Henderson, D. R. Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res., 57: 2559-2563, 1997.
3. Fueyo, J., Gomez-Manzano, C., Alemany, R., Lee, P. S., McDonnell, T. J., Mitlianga, P., Shi, Y. X., Levin, V. A., Yung, W. K., and Kyritsis, A. P. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene, 19: 2-12, 2000.
4. Heise, C., Hermiston, T., Johnson, L., Brooks, G., Sampson-Johannes, A., Williams, A., Hawkins, L., and Kirn, D. An adenovirus E1A mutant that demonstrates potent and selective systemic antitumoral efficacy. Nat. Med., 6: 1134-1139, 2000.
5. Martuza, R. L. Conditionally replicating herpes vectors for cancer therapy. J. Clin. Investig., 105: 841-846, 2000.
6. Bergmann, M., Romirer, I., Sachet, M., Fleischhacker, R., Garcia-Sastre, A., Palese, P., Wolff, K., Pehamberger, H., Jakesz, R., and Muster, T. A genetically engineered influenza A virus with ras-dependent oncolytic properties. Cancer Res., 61: 8188-8193, 2001.
7. Phuangsab, A., Lorence, R. M., Reichard, K. W., Peeples, M. E., and Walter, R. J. Newcastle disease virus therapy of human tumor xenografts: Antitumor effects of local or systemic administration. Cancer Lett., 172: 27-36, 2001.
8. Schirrmacher, V., Griesbach, A., and Ahlert, T. Antitumor effects of Newcastle disease virus in vivo: Local versus systemic effects. Int. J. Oncol., 18: 945-952, 2001.
9. Gromeier, M., Lachmann, S., Rosenfeld, M. R., Gutin, P. H., and Wimmer, E. Intergeneric poliovirus recombinants for the treatment of malignant glioma. Proc. Natl. Acad. Sci. USA, 97: 6803-6808, 2000.
10. Strong, J. E., Coffey, M. C., Tang, D., Sabinin, P., and Lee, P. W. The molecular basis of viral oncolysis: Usurpation of the Ras signaling pathway by reovirus. EMBO J., 17: 3351-3362, 1998.
11. Wilcox, M. E., Yang, W., Senger, D., Rewcastle, N. B., Morris, D. G., Brasher, P. M., Shi, Z. Q., Johnston, R. N., Nishikawa, S., Lee, P. W., and Forsyth, P. A. Reovirus as an oncolytic agent against experimental human malignant gliomas. J. Natl. Cancer Inst. (Bethesda), 93: 903-912, 2001.
12. Timiryasova, T. M., Li, J., Chen, B., Chong, D., Langridge, W. H., Gridley, D. S., and Fodor, I. Antitumor effect of vaccinia virus in glioma model. Oncol. Res., 11: 133-144, 1999.
13. McCart, J. A., Ward, J. M., Lee, J., Hu, Y., Alexander, H. R., Libutti, S. K., Moss, B., and Bartlett, D. L. Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res., 61: 8751-8757, 2001.
14. Stojdl, D. F., Lichty, B., Knowles, S., Marius, R., Atkins, H., Sonenberg, N., and Bell, J. C. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat. Med., 6: 821-825, 2000.
15. Curiel, D. T. The development of conditionally replicative adenoviruses for cancer therapy. Clin. Cancer Res., 6: 3395-3399, 2000.
16. Hallenbeck, P. L., Chang, Y. N., Hay, C., Golightly, D., Stewart, D., Lin, J., Phipps, S., and Chiang, Y. L. A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. Hum. Gene Ther., 10: 1721-1733, 1999.
17. Kurihara, T., Brough, D. E., Kovesdi, I., and Kufe, D. W. Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. J. Clin. Investig., 106: 763-771, 2000.
18. Matsubara, S., Wada, Y., Gardner, T. A., Egawa, M., Park, M. S., Hsieh, C. L., Zhau, H. E., Kao, C., Kamidono, S., Gillenwater, J. Y., and Chung, L. W. A conditional replication-competent adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis. Cancer Res., 61: 6012-6019, 2001.
19. Hernandez-Alcoceba, R., Pihalja, M., Nunez, G., and Clarke, M. F. Evaluation of a new dual-specificity promoter for selective induction of apoptosis in breast cancer cells. Cancer Gene Ther., 8: 298-307, 2001.
20. Brunori, M., Malerba, M., Kashiwazaki, H., and Iggo, R. Replicating adenoviruses that target tumors with constitutive activation of the wnt signaling pathway. J. Virol., 75: 2857-2865, 2001.
21. Adachi, Y., Reynolds, P. N., Yamamoto, M., Wang, M., Takayama, K., Matsubara, S., Muramatsu, T., and Curiel, D. T. A midkine promoter-based conditionally replicative adenovirus for treatment of pediatric solid tumors and bone marrow tumor purging. Cancer Res., 61: 7882-7888, 2001.
22. Kirn, D. Oncolytic virotherapy for cancer with the adenovirus d11520 (Onyx-015): Results of Phase I and II trials. Expert. Opin. Biol. Ther., 1: 525-538, 2001.
23. DeWeese, T. L., van der Poel, H., Li, S., Mikhak, B., Drew, R., Goemann, M., Hamper, U., DeJong, R., Detorie, N., Rodriguez, R., Haulk, T., DeMarzo, A. M., Piantadosi, S., Yu, D. C., Chen, Y., Henderson, D. R., Carducci, M. A., Nelson, W. G., and Simons, J. W. A Phase I trial of CV706, a replication-competent. PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res., 61: 7464-7472, 2001.
24. Ganly, I., Eckhardt, S. G., Rodriguez, G. I., Soutar, D. S., Otto, R., Robertson, A. G., Park, O., Gulley, M. L., Heise, C., Von Hoff, D. D., and Kaye, S. B. A Phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin. Cancer Res., 6: 798-806, 2000.
25. Nemunaitis, J., Khuri, F., Ganly, I., Arseneau, J., Posner, M., Vokes, E., Kuhn, J., McCarty, T., Landers, S., Blackburn, A., Romel, L., Randlev, B., Kaye, S., and Kirn, D. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J. Clin. Oncol., 19: 289-298, 2001.
26. Suzuki, K., Fueyo, J., Krasnykh, V., Reynolds, P. N., Curiel, D. T., and Alemany, R. A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency. Clin. Cancer Res., 7: 120-126, 2001.
27. Shinoura, N., Yoshida, Y., Tsunoda, R., Ohashi, M., Zhang, W., Asai, A., Kirino, T., and Hamada, H. Highly augmented cytopathic effect of a fiber-mutant E1B-defective adenovirus for gene therapy of gliomas. Cancer Res., 59: 3411-3416, 1999.
28. Heise, C., Sampson-Johannes, A., Williams, A., McCormick, F., Von Hoff, D. D., and Kirn, D. H. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat. Med., 3: 639-645, 1997.
29. Khuri, F. R., Nemunaitis, J., Ganly, I., Arseneau, J., Tannock, I. F., Romel, L., Gore, M., Ironside, J., MacDougall, R. H., Heise, C., Randlev, B., Gillenwater, A. M., Bruso, P., Kaye, S. B., Hong, W. K., and Kirn, D. H. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat. Med., 6: 879-885, 2000.
30. Rogulski, K. R., Freytag, S. O., Zhang, K., Gilbert, J. D., Paielli, D. L., Kim, J. H., Heise, C. C., and Kirn, D. H. In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy. Cancer Res., 60: 1193-1196, 2000.
31. Yu, D. C., Chen, Y., Dilley, J., Li, Y., Embry, M., Zhang, H., Nguyen, N., Amin, P., Oh, J., and Henderson, D. R. Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel. Cancer Res., 61: 517-525, 2001.
32. Wildner, O., Blaese, R. M., and Morris, J. C. Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase. Cancer Res., 59: 410-413, 1999.
33. Freytag, S. O., Rogulski, K. R., Paielli, D. L., Gilbert, J. D., and Kim, J. H. A novel three-pronged approach to kill cancer cells selectively: Concomitant viral, double suicide gene, and radiotherapy. Hum. Gene Ther., 9: 1323-1333, 1998.
34. Lambright, E. S., Amin, K., Wiewrodt, R., Force, S. D., Lanuti, M., Propert, K. J., Litzky, L., Kaiser, L. R., and Albelda, S. M. Inclusion of the herpes simplex thymidine kinase gene in a replicating adenovirus does not augment antitumor efficacy. Gene Ther., 8: 946-953, 2001.
35. Grunhaus, A., and Horwitz, M. S. Adenoviruses as cloning vectors. Semin. Virol., 3: 237-252, 1992.
36. Yeh, P., and Perricaudet, M. Advances in adenoviral vectors: From genetic engineering to their biology. FASEB J., 11: 615-623, 1997.
37. Hawkins, L. K., Johnson, L., Bauzon, M., Nye, J. A., Castro, D., Kitzes, G. A., Young, M. D., Holt, J. K., Trown, P., and Hermiston, T. W. Gene delivery from the E3 region of replicating human adenovirus: Evaluation of the 6.7 K/gp19 K region. Gene Ther., 8: 1123-1131, 2001.
38. Tollefson, A. E., Ryerse, J. S., Scaria, A., Hermiston, T. W., and Wold, W. S. The E3-11.6-kDa adenovirus death protein (ADP) is required for efficient cell death: Characterization of cells infected with adp mutants. Virology, 220: 152-162, 1996.
39. Tollefson, A. E., Scaria, A., Saha, S. K., and Wold, W. S. The 11, 600-MW protein encoded by region E3 of adenovirus is expressed early but is greatly amplified at late stages of infection. J. Virol., 66: 3633-3642, 1992.
40. Tollefson, A. E., Scaria, A., Hermiston, T. W., Ryerse, J. S., Wold, L. J., and Wold, W. S. The adenovirus death protein (E3-11.6K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells. J. Virol., 70: 2296-2306, 1996.
41. Yu, D. C., Chen, Y., Seng, M., Dilley, J., and Henderson, D. R. The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts. Cancer Res., 59: 4200-4203, 1999.
42. Schutte, M., Hruban, R. H., Geradts, J., Maynard, R., Hilgers, W., Rabindran, S. K., Moskaluk, C. A., Hahn, S. A., Schwarte-Waldhoff, I., Schmiegel, W., Baylin, S. B., Kern, S. E., and Herman, J. G. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res., 57: 3126-3130, 1997.
43. Wolf, J. K., Kim, T. E., Fightmaster, D., Bodurka, D., Gershenson, D. M., Mills, G., and Wharton, J. T. Growth suppression of human ovarian cancer cell lines by the introduction of a p16 gene via a recombinant adenovirus. Gynecol. Oncol., 73: 27-34, 1999.
44. Kawabe, S., Roth, J. A., Wilson, D. R., and Meyn, R. E. Adenovirus-mediated p16INK4a gene expression radiosensitizes non-small cell lung cancer cells in a p53-dependent manner. Oncogene, 19: 5359-5366, 2000.
45. Egan, C., Jelsma, T. N., Howe, J. A., Bayley, S. T., Ferguson, B., and Branton, P. E. Mapping of cellular protein-binding sites on the products of early-region 1A of human adenovirus type 5. Mol. Cell. Biol., 8: 3955-3959, 1988.
46. Maizel, J. V., Jr., White, D. O., and Scharff, M. D. The polypeptides of adenovirus. 1. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12. Virology, 36: 115-125, 1968.
47. Alemany, R., Dai, Y., Lou, Y. C., Sethi, E., Prokopenko, E., Josephs, S. F., and Zhang, W. W. Complementation of helper-dependent adenoviral vectors: Size effects and titer fluctuations. J. Virol. Methods, 68: 147-159, 1997.
48. Alemany, R., Suzuki, K., and Curiel, D. T. Blood clearance rates of adenovirus type 5 in mice. J. Gen. Virol., 81: 2605-2609, 2000.
49. Chartier, C., Degryse, E., Gantzer, M., Dieterle, A., Pavirani, A., and Mehtali, M. Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. J. Virol., 70: 4805-4810, 1996.
50. Dmitriev, I., Krasnykh, V., Miller, C. R., Wang, M., Kashentseva, E., Mikheeva, G., Belousova, N., and Curiel, D. T. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a Coxsackie virus and adenovirus receptor-independent cell entry mechanism. J. Virol., 72: 9706-9713, 1998.
51. O'Carroll, S. J., Hall, A. R., Myers, C. J., Braithwaite, A. W., and Dix, B. R. Quantifying adenoviral titers by spectrophotometry. Biotechniques, 28: 408-410, 412, 2000.
52. Mauceri, H. J., Hanna, N. N., Beckett, M. A., Gorski, D. H., Staba, M. J., Stellato, K. A., Bigelow, K., Heimann, R., Gately, S., Dhanabal, M., Soff, G. A., Sukhatme, V. P., Kufe, D. W., and Weichselbaum, R. R. Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature (Lond.), 394: 287-291, 1998.
53. Wesseling, J. G., Bosma, P. J., Krasnykh, V., Kashentseva, E. A., Blackwell, J. L., Reynolds, P. N., Li, H., Parameshwar, M., Vickers, S. M., Jaffee, E. M., Huibregtse, K., Curiel, D. T., and Dmitriev, I. Improved gene transfer efficiency to primary and established human pancreatic carcinoma target cells via epidermal growth factor receptor and integrin-targeted adenoviral vectors. Gene Ther., 8: 969-976, 2001.
54. You, Z., Fischer, D. C., Tong, X., Hasenburg, A., Aguilar-Cordova, E., and Kieback, D. G. Coxsackievirus-adenovirus receptor expression in ovarian cancer cell lines is associated with increased adenovirus transduction efficiency and transgene expression. Cancer Gene Ther., 8: 168-175, 2001.
55. McDonald, D., Stockwin, L., Matzow, T., Blair Zajdel, M. E., and Blair, G. E. Coxsackie and adenovirus receptor (CAR)-dependent and major histocompatibility complex (MHC) class I-independent uptake of recombinant adenoviruses into human tumour cells. Gene Ther., 6: 1512-1519, 1999.
56. 5 may predict the susceptibility to adenovirus-mediated gene transfer in human lung cancer cells. Gene Ther., 5: 361-368, 1998.
57. Alemany, R., Balague, C., and Curiel, D. T. Replicative adenoviruses for cancer therapy. Nat. Biotechnol., 18: 723-727, 2000.
58. Green, M., Pina, M., and Kimes, R. C. Biochemical studies on adenovirus multiplication. XII. Plaquing efficiencies of purified human adenoviruses. Virology, 31: 562-565, 1967.
59. Mittereder, N., March, K. L., and Trapnell, B. C. Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J. Virol., 70: 7498-7509, 1996.
60. Harrison, D., Sauthoff, H., Heitner, S., Jagirdar, J., Rom, W. N., and Hay, J. G. Wild-type adenovirus decreases tumor xenograft growth, but despite viral persistence complete tumor responses are rarely achieveddeletion of the viral E1b-19-kD gene increases the viral oncolytic effect. Hum. Gene Ther., 12: 1323-1332, 2001.
61. Hawkins, L. K., and Hermiston, T. Gene delivery from the E3 region of replicating human adenovirus: Evaluation of the E3B region. Gene Ther., 8: 1142-1148, 2001.
62. Hawkins, L. K., and Hermiston, T. W. Gene delivery from the E3 region of replicating human adenovirus: Evaluation of the ADP region. Gene Ther., 8: 1132-1141, 2001.
63. Gooding, L. R., Ranheim, T. S., Tollefson, A. E., Aquino, L., Duerksen-Hughes, P., Horton, T. M., and Wold, W. S. The 10,400- and 14,500-dalton proteins encoded by region E3 of adenovirus function together to protect many but not all mouse cell lines against lysis by tumor necrosis factor. J. Virol., 65: 4114-4123, 1991.
64. Elsing, A., and Burgert, H. G. The adenovirus E3/10.4K-14.5K proteins down-modulate the apoptosis receptor Fas/Apo-1 by inducing its internalization. Proc. Natl. Acad. Sci. USA, 95: 10072-10077, 1998.
65. Burgert, H. G., Maryanski, J. L., and Kvist, S. "E3/19K" protein of adenovirus type 2 inhibits lysis of cytolytic T lymphocytes by blocking cell-surface expression of histocompatibility class I antigens. Proc. Natl. Acad. Sci. USA, 84: 1356-1360, 1987.
66. Doronin, K., Toth, K., Kuppuswamy, M., Ward, P., Tollefson, A. E., and Wold, W. S. Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein. J. Virol., 74: 6147- 6155, 2000.
67. Doronin, K., Kuppuswamy, M. Toth, K., Tollefson, A. E., Krajcsi, P., Krougliak, V., and Wold, W. S. Tissue-specific, tumor-selective, replication-competent adenovirus vector for cancer gene therapy. J. Virol., 75: 3314-3324, 2001.